Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway

Journals Menu

Follow SCIRP

ISSN Print: 2163-9914
ISSN Online: 2164-005X
www.scirp.org/journal/ojra
E-mail: ojra@scirp.org

Citations

"Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway"
written by Jun Shiota, Hidetoshi Murao, Akihiko Miura, Masaaki Mikami, Keiichi Tanaka,
published by Open Journal of Rheumatology and Autoimmune Diseases, Vol.6 No.4, 2016

has been cited by the following article(s):

[1]	Highly Efficient Oral Iguratimod/Polyvinyl Alcohol Nanodrugs Fabricated by High‐Gravity Nanoprecipitation Technique for Treatment of Rheumatoid Arthritis
	Small, 2024

[2]	Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways
	2021

Follow SCIRP

Free SCIRP Newsletters

Add your e-mail address to receive free newsletters from SCIRP.

Top